Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: des IGF-1 evidence and risks
Also known as: Des(1-3) IGF-1, IGF1 DES
IGF-1 DES (Des(1-3) IGF-1) is an N-terminally truncated variant of IGF-1 lacking the first three amino acids, which reduces IGFBP binding even further than IGF-1 LR3's substitution/extension approach - resulting in reports of greater potency at the IGF-1 receptor, but at the cost of a very short half-life that researchers note requires immediate post-workout/post-activity administration in study protocols to capture the acute signaling window.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Animal comparative pharmacology, receptor-binding research, and current WADA status
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The bilateral post-workout injection schedules were bodybuilding conventions and were removed. The cited potency evidence is from pigs and marmosets, not controlled human administration.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention IGF-1 DES or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.